Trial Profile
Exploratory Trial to Assess Mechanism of Action, Clinical Effect, Safety and Tolerability of 12 Weeks of Treatment With BI 655130 in Patients With Active Ulcerative Colitis (UC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Apr 2022
Price :
$35
*
At a glance
- Drugs Spesolimab (Primary)
- Indications Ulcerative colitis
- Focus Pharmacodynamics; Pharmacogenomic
- Sponsors Boehringer Ingelheim
- 30 Oct 2019 Status changed from active, no longer recruiting to completed.
- 23 Oct 2019 Planned End Date changed from 22 Oct 2019 to 24 Oct 2019.
- 16 Sep 2019 Planned End Date changed from 28 Aug 2019 to 22 Oct 2019.